Racura Oncology (ASX:RAC) Risk Assessment


ASX:RAC Racura Oncology Ltd ASX:RAC
31 GF Score
Price A$2.20
View Full Analysis

What is Racura Oncology Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Racura Oncology is: No Data: Cannot be evaluated.

Racura Oncology  (ASX:RAC) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Racura Oncology Risk Assessment Related Terms

ASX:RAC vs VRTX, REGN, ALNY: Risk Assessment Comparison

For the Biotechnology subindustry, Racura Oncology's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Racura Oncology Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Racura Oncology's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Racura Oncology's Risk Assessment falls into.


ASX:RAC
31GF Score
Racura Oncology Ltd ASX:RAC
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Racura Oncology Business Description

Other Exchanges FN3:Germany
Address 1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
31GF Score

Get the complete analysis for ASX:RAC

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.20
Price